Trinity Biotech (TRIB) Return on Capital Employed (2009 - 2024)

Trinity Biotech has disclosed Return on Capital Employed across 16 years of filings, most recently posting 31.0% for Q4 2024.

• Return on Capital Employed for Q4 2024 came in at 31.0%, up 2720.0% year-over-year; the trailing twelve-month figure through Dec 2024 was 31.0% (up 2720.0% YoY), and the FY2025 annual result was 42.69%, up 8565.0% from the prior year.
• Return on Capital Employed came in at 31.0% for Q4 2024 at Trinity Biotech, down from 19.79% in the prior quarter.
• In the past five years, Return on Capital Employed ranged from a high of 86.72% in Q2 2021 to a low of 58.2% in Q4 2023.
• The 5-year median for Return on Capital Employed is 5.91% (2022), against an average of 5.08%.
• Across the five-year window, Return on Capital Employed surged 8204 bps in 2021 and sank 8644 bps in 2022, its largest moves.
• Trinity Biotech's Return on Capital Employed stood at 19.16% in 2020, then jumped by 70 bps to 32.57% in 2021, then plunged by 177 bps to 24.92% in 2022, then slumped by 134 bps to 58.2% in 2023, then soared by 47 bps to 31.0% in 2024.
• The last three Return on Capital Employed figures came in at 31.0% (Q4 2024), 19.79% (Q3 2024), and 23.09% (Q2 2024), per Business Quant data.